Accreditation Information and Learning Objectives

Learning Objectives:

After reading this Clinical Proceedings^®, participants will be able to:

• State the efficacy of the single-rod implant
• List four features of the single-rod implant
• Identify two possible side effects of the single-rod implant
• Discuss the clinical expectations and management of unscheduled bleeding with the single-rod implant
• Describe the steps for insertion and removal of the single-rod implant

Supporter Acknowledgement

Funding for the publication was provided by an educational grant from Organon, a part of Schering-Plough Corporation.

Clinical Advisors

David F. Archer, MD
Wendy Grube, MSN, CRNP
Emily Rowe, PharmD

This publication is part of an ARHP program that also included the following advisors: Kurt Barnhart, MD, MSCE, Barbara Clark, PA-C, MPAS, Mitchell Creinin, MD, Philip Darney, MD, MSc, Patricia Murphy, CNM, DrPH, and Lee Shulman, MD.

Contributing Staff and Consultants

Shama Alam, MScPH, Education Associate
Jenn Baldwin, Consulting Designer
Beth Jordan, MD, Medical Director
Allison Tombros Korman, MHS, Associate Director of Education
Barbara Rinehart, MS, Consulting Writer
Wayne C. Shields, President and CEO
Amy M. Swann, MA, Director of Education

Financial Disclosure Information

The following contributors have a financial interest or affiliation with the manufacturers of commercial products possibly related to topics covered in this issue of Clinical Proceedings. These financial interests or affiliations are in the form of grants, research support, speaker support, or other support. This support is noted to fully inform readers and should not have an adverse impact on the information provided within this publication.

Archer: Industry consultant for Agile Therapeutics, Bayer Schering AG, Bayer HealthCare Pharmaceuticals, Johnson & Johnson, Merck, Novo Nordisk, Ortho McNeil, Organon, Solvay,Warner Chilcott Pharmaceuticals, and Wyeth Laboratories; Receives industry research support from Bayer HealthCare Pharmaceuticals, Duramed, Organon, Solvay, Warner Chilcott, and Wyeth Laboratories; Receives direct industry lecture fees from Novo Nordisk, Organon, Bayer HealthCare Pharmaceuticals, and Wyeth Laboratories.

Barnhart: Has been/is an investigator for clinical trials for Boehringer Ingelheim, Duramed, Johnson & Johnson, MGI Pharma, Organon, Pfizer, Third Wave, Wyeth-Ayerst, and Xanodyne; Consultant for Novo Nordisk; Part of the Speaker's Bureau for Organon and Wyeth-Ayerst.

Creinin: Receives grants/research support from Organon and Bayer HealthCare Pharmaceuticals; Consultant for Organon and Bayer HealthCare Pharmaceuticals.

Darney: Consultant for Organon; Speaker for Organon.

Grube: Speaker for Organon.

Shulman: Receives grants/research support from Barr-Duramed and Wyeth; Consultant for Barr-Duramed, Ortho-McNeil, Bayer HealthCare Pharmaceuticals, and Organon; Speaker for Bayer HealthCare Pharmaceuticals, Organon, Ortho-McNeil, Barr-Duramed, GlaxoSmithKline, and Roche.

Alam, Baldwin, Clark, Jordan, Korman, Murphy, Rowe, Shannon, Shields, and Swann have no affiliations to disclose.

Accreditation/Credit Designation

Participants who correctly answer at least 70% of the post-test questions will receive continuing education credit. If you have any questions, please contact ARHP staff at (202) 466-3825 or arhp@arhp.org. You will receive a certificate of completion within four weeks of submitting the post-test.

Nurses and Nurse Practitioners – This educational activity has been approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for 2 contact hours, including 1.2 pharmacology hours. Credit can be applied toward the nursing continuing education requirements of most professional organizations and state Boards of Nursing.

Nurse Midwives – ACCME credit hours in Category 1 are accepted by the Continuing Competency Assessment Program of the American College of Nurse Midwives for programs relevant to nurse midwifery. Nurse Midwives who complete this activity may report up to 2 hours of credit.

Pharmacists – ARHP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The assigned universal program number is 463-000-08-008-H04-P. This activity provides 2 contact hours of continuing education credit.

Physicians – ARHP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education (CME) for physicians. ARHP designates this continuing medical education activity for 2 credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

Physician Assistants – The American Academy of Physician Assistants accepts Category 1 CME approval from organizations accredited by the ACCME. Physician Assistants who complete this activity may report up to 2 hours of credit.